Since 2007, the US government has attempted to draw companies into this sparsely occupied space by creating an incentive program. Manufacturers who license products for specified “neglected” diseases are granted the right to an expedited Food and Drug Administration review when they want to bring another product to market.
It seems like a good idea — and may still be. But a number of groups that supported the program aren’t happy with how it is playing out so far. Let’s explore why.
Read Full Article »